Per favorire la ricerca oncologica finalizzata alla prevenzione, diagnosi, cura e riabilitazione, lo Stato ha destinato risorse aggiuntive e ha promosso un programma straordinario a carattere nazionale per l’anno 2006, comprensivo anche di progetti di innovazione tecnologica e di progetti di collaborazione internazionale.
Nel bando del 2006 si sono distinte due tipologie di proposta:
Ai Progetti Ordinari del Programma straordinario per la ricerca oncologica sono state riservate, in prima istanza, risorse pari al 30% (21 milioni di euro) del fondo complessivo (70 milioni di euro) messo a disposizione per il Bando della ricerca oncologica.
| Ente | Progetto | Finanziamento |
|---|---|---|
| Regione Campania | Detection of cancer-causing mutations by innovative high-throughput technological platforms | 165.000,00 |
| Regione Campania | Molecular diagnostic and prognostic markers of thyroid neoplasias | 504.000,00 |
| Regione Emilia Romagna | Biological predictive factors of response to target therapies in lung cancer | 296.000,00 |
| Regione Emilia Romagna | Biomarkers discovery for the early diagnosis and for proteomic classification of Hepatocellular Carcinoma | 837.000,00 |
| Regione Emilia Romagna | Characterization of normal and neoplastic hematopoietic stem cells for the clinical use for tissue regeneration and the development of novel anti-tumor targeted therapies | 220.000,00 |
| Regione Emilia Romagna | Post-genomic approaches for the identification of highrisk cancers: evaluation and optimization of costs/benefits for the National Health System | 462.000,00 |
| Regione Liguria | Hereditary, molecular and environmental factors in the pancreatic cancer early diagnosis | 248.000,00 |
| Regione Liguria | Identification of tumor biomarkers through a biologydriven integrated approach | 498.000,00 |
| Regione Lombardia | Humanization of cancer care in Italy: implementation of evidence-based recommendations (HUCARE project) | 544.000,00 |
| Regione Lombardia | Use of integrated PET/CT as a first line re-staging technique in oncological patients | 316.000,00 |
| Regione Sicilia | Molecular mechanisms controlling cancer stem cells survival | 1.239.000,00 |
| Regione Umbria | Multicentric randomized study comparing gefitinib versus platinum-based chemotherapy in EGFR fish positive NSCLC patients | 120.000,00 |
| Regione Veneto | Identification of novel molecular targets in pancreatic cancer by analysis of tumor-stroma interaction | 148.000,00 |
| Regione Veneto | Signalling Molecules as Targets for New Antineoplastic Strategies | 300.000,00 |
| Istituto neurologico Carlo Besta - Milano | Epigenetics and post-transcriptional regulation in cancer stem-like cells from glioblastoma multiforme | 314.000,00 |
| Istituto neurologico Carlo Besta - Milano | Role of Brain Mapping in the surgical treatment of low grade gliomas | 578.000,00 |
| Casa sollievo della sofferenza - San Giovanni Rotondo | HRPT2 gene and the WNT pathway: new insights in the genetics of parathyroid and biliary ducts carcinomas | 385.000,00 |
| Istituto Giannina Gaslini - Genova | Health status of adults survivors of childhood cancer | 400.000,00 |
| Istituto Giannina Gaslini - Genova | New Immunotherapeutic Approaches to Neuroblastoma | 740.000,00 |
| Istituto clinico Humanitas - Ancona | Innate immunity and gastrointestinal cancer as paradigm: from new molecules to the bed side | 703.000,00 |
| Istituto Oncologico Veneto - Padova | Angiogenesis at the interface between tumor and microenvironment: biological studies and therapeutic implications in haematologic malignancies | 374.000,00 |
| Istituto Europeo di Oncologia - Milano | Biological and molecular characterization of cancer stem cells | 895.000,00 |
| Istituto Europeo di Oncologia - Milano | Surrogate markers of antiangiogenic therapy in triple receptor negative breast cancer | 295.000,00 |
| Istituto nazionale per la ricerca sul cancro - Genova | Targeting tumor-related immunosuppression for new combined approaches of immunotherapy | 340.000,00 |
| Istituto Dermopatico dell'Immacolata - Roma | Antivascular therapy in melanoma: from preclinical to clinical studies | 809.000,00 |
| Istituto Dermopatico dell'Immacolata - Roma | Molecular characterization of melanoma cancer stem cells | 950.000,00 |
| Istituto nazionale dei tumori - Milano | Controlled Extension of Conventional Criteria for Liver Transplantation in Hepatocarcinoma (HCC): a prospective validation study | 315.000,00 |
| Istituto nazionale dei tumori - Milano | Tumor radioresistance and predictive markers of the response to radiotherapy | 310.000,00 |
| Centro cardiologico Monzino - Milano | Characterization of molecules involved in tumor angiogenesis regulation | 835.000,00 |
| Istituto nazionale tumori Fondazione Pascale | Pyrrolo benzothiadiazepines as new agents for targeting tumor and stromal cell populations in multiple myeloma and chronic lymphocytic leukemia | 505.000,00 |
| Istituti ortopedici Rizzoli - Bologna | Genes regulating osteoblastogenesis as new therapeutic targets for bone tumors | 325.000,00 |
| Istituto dermatologico San Gallicano - Roma | Cell signaling in human melanoma: identification of genetic and epigenetic mechanism potentially relevant for clinical management | 389.000,00 |
| Policlinico San Matteo - Pavia | Identification of new histologic, phenotypic and molecular types of gastric cancer for prognosis predictive classification, early diagnosis and improved therapy | 225.000,00 |
| Fondazione San Raffaele del Monte Tabor - Milano | New murine models of tumors: new avenues for the identification of novel oncogenes and therapeutic strategies | 999.000,00 |
| Istituto nazionale per le malattie infettive Spallanzani - Roma | Neoangiogenesis in hepatoma and other tumors: novel therapeutical targeting of endothelial precursors | 880.000,00 |
| Istituto Superiore di Sanità | Identification and therapeutic targeting of new oncogenetic molecules in human tumors: basic, preclinical and clinical studies | 692.000,00 |
| Istituto Superiore di Sanità | New therapeutic strategies based on studies of tumor microenvironment and new targets identified through proteomic and genomic profile analysis | 1.073.000,00 |
| Istituto Superiore di Sanità | Use of HIV protease inhibitors to block HIV negative cervical cancer progression and recurrence | 1.260.000,00 |
| Istituto Superiore per la Prevenzione e Sicurezza sul Lavoro | Novel approaches to assess the carcinogenic potential of genotoxic pollutants | 326.000,00 |
| Istituto Zooprofilattico Sperimentale della Sicilia | Vaccination against spontaneous canine breast carcinomas with an experimental DNA vaccine (immunization against the proto-oncogene Her-2/neu) | 186.000,00 |
| TOTALE |
|
21.000.000 |
Data di ultimo aggiornamento 9 dicembre 2021
